| Symbol | PRLD |
|---|---|
| Name | PRELUDE THERAPEUTICS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 175 INNOVATION BOULEVARD, WILMINGTON, DE 19805 |
| Telephone | (302) 467-1280 |
| Fax | — |
| — | |
| Website | https://www.preludetx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001678660 |
| Description | Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Additional info from NASDAQ: |
BAKER BROS. ADVISORS LP 🟢 acquired 76.0K shares (2 derivative) of Prelude Therapeutics Inc (PRLD) at $3.94 Transaction Date: Jun 09, 2026 | Filing ID: 265965
Read moreDorton Katina 🟢 acquired 38.0K shares (1 derivative) of Prelude Therapeutics Inc (PRLD) at $3.94 Transaction Date: Jun 09, 2026 | Filing ID: 000005
Read moreBonita David P 🟢 acquired 38.0K shares (1 derivative) of Prelude Therapeutics Inc (PRLD) at $3.94 Transaction Date: Jun 09, 2026 | Filing ID: 000003
Read moreSandor Victor 🟢 acquired 38.0K shares (1 derivative) of Prelude Therapeutics Inc (PRLD) at $3.94 Transaction Date: Jun 09, 2026 | Filing ID: 000003
Read moreFRIEDMAN PAUL A 🟢 acquired 38.0K shares (1 derivative) of Prelude Therapeutics Inc (PRLD) at $3.94 Transaction Date: Jun 09, 2026 | Filing ID: 000003
Read more(30% Negative) PRELUDE THERAPEUTICS INC (PRLD) Reports Q2 2026 Financial Results
Read morePrelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Read moreMorris Charles Q 🟢 acquired 450.0K shares (1 derivative) of Prelude Therapeutics Inc (PRLD) at $4.70 ($2.1M) Transaction Date: May 01, 2026 | Filing ID: 000004
Read moreNew Form ARS - Prelude Therapeutics Inc <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001193125-26-191603 <b>Size:</b> 1 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07469891 | A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neop… | Phase1 | Polycythemia Vera (PV) | Recruiting | 2026-04-29 | 2028-04-01 | ClinicalTrials.gov |
| NCT06682806 | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced … | Phase2 | Advanced Solid Tumor | Terminated | 2025-06-03 | 2026-01-23 | ClinicalTrials.gov |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Meta… | Phase1 | Advanced Solid Tumor | Terminated | 2024-11-04 | 2026-01-28 | ClinicalTrials.gov |
| NCT05665530 | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venet… | Phase1 | Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) | Completed | 2023-09-12 | 2026-01-21 | ClinicalTrials.gov |
| NCT05639751 | PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Meta… | Phase1 | Advanced Solid Tumor | Completed | 2023-05-02 | 2025-10-01 | ClinicalTrials.gov |
| NCT05538572 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tum… | Phase1 | Breast Cancer | Completed | 2022-12-27 | 2024-06-26 | ClinicalTrials.gov |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R … | Phase1 | Acute Myeloid Leukemia | Terminated | 2022-03-22 | 2024-01-19 | ClinicalTrials.gov |
| NCT05159518 | A Study of PRT2527 in Participants With Advanced Solid Tumors | Phase1 | Sarcoma | Completed | 2022-02-14 | 2023-12-06 | ClinicalTrials.gov |
| NCT04837677 | A Study of PRT1419 in Patients With Advanced Solid Tumors | Phase1 | Sarcoma | Completed | 2021-08-11 | 2023-02-06 | ClinicalTrials.gov |
| NCT04916808 | The AUS-PREDICT Registry for DCIS Patients With DCISionRT Testing | — | DCIS | Active_Not_Recruiting | 2021-07-02 | 2035-12-01 | ClinicalTrials.gov |
| NCT04543305 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | Phase1 | Multiple Myeloma | Completed | 2020-09-28 | 2022-03-21 | ClinicalTrials.gov |
| NCT04089449 | A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and … | Phase1 | Advanced Solid Tumor | Completed | 2019-11-06 | 2023-03-28 | ClinicalTrials.gov |
| NCT03886831 | A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Ma… | Phase1 | Relapsed/Refractory Advanced Solid Tumors | Completed | 2019-02-11 | 2022-11-16 | ClinicalTrials.gov |
| NCT03448926 | The PREDICT Registry: | — | DCIS | Recruiting | 2018-02-27 | 2036-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT1419 | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04543305 |
| PRT1419 | Other | Phase PHASE1 | Sarcoma | COMPLETED | NCT04837677 |
| PRT543 | Other | Phase PHASE1 | Relapsed/Refractory Advanced Solid Tumors | COMPLETED | NCT03886831 |
| PRT811 | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT04089449 |
| PRT2527 | Other | Phase PHASE1 | Sarcoma | COMPLETED | NCT05159518 |
| Venetoclax | Other | Phase PHASE1 | Acute Myeloid Leukemia | TERMINATED | NCT05107856 |
| Azacitidine | Other | Phase PHASE1 | Acute Myeloid Leukemia | TERMINATED | NCT05107856 |
| PRT1419 | Other | Phase PHASE1 | Acute Myeloid Leukemia | TERMINATED | NCT05107856 |
| PRT3645 | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT05538572 |
| DCISionRT Test | Other | Preclinical | DCIS | ACTIVE_NOT_RECRUITING | NCT04916808 |
| DCISionRT Test | Other | Preclinical | DCIS | ACTIVE_NOT_RECRUITING | NCT04916808 |
| Docetaxel | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT05639751 |
| PRT3789 | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT05639751 |
| Venetoclax | Other | Phase PHASE1 | Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) | COMPLETED | NCT05665530 |
| Zanubrutinib | Other | Phase PHASE1 | Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) | COMPLETED | NCT05665530 |
| PRT2527 | Other | Phase PHASE1 | Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) | COMPLETED | NCT05665530 |
| pembrolizumab | Other | Phase PHASE2 | Advanced Solid Tumor | TERMINATED | NCT06682806 |
| PRT3789 | Other | Phase PHASE2 | Advanced Solid Tumor | TERMINATED | NCT06682806 |
| PRT7732 | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT06560645 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| 7-gene biosignature | Other | Preclinical | DCIS | RECRUITING | NCT03448926 |
| Treatment recommendation surveys | Drug | Preclinical | DCIS | RECRUITING | NCT03448926 |
| 7-gene biosignature | Other | Preclinical | DCIS | RECRUITING | NCT03448926 |
| Treatment recommendation surveys | Drug | Preclinical | DCIS | RECRUITING | NCT03448926 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| PRT12396 | Other | Phase PHASE1 | Polycythemia Vera (PV) | RECRUITING | NCT07469891 |
| 7-gene biosignature | Other | Preclinical | DCIS | RECRUITING | NCT03448926 |
| Treatment recommendation surveys | Drug | Preclinical | DCIS | RECRUITING | NCT03448926 |